T cells play a critical role in immune surveillance at mucosal surfaces. SHIP1 −/− mice succumb to mucosal inflammatory disease that afflicts the lung and small intestine. The basis of this condition has not been defined. Here we show that SHIP1 is required for the normal persistence and survival of T cells in mucosal tissues. We find that CD4 and CD8 effector T cells are reduced, but Treg cells increased in the SI and lungs of SHIP1 −/− and CD4CreSHIP flox/flox mice. Furthermore, a subset of T cells in the SI of SHIP1 −/− mice are FasL+ and are more susceptible to extrinsic cell death. Mechanistic analyses showed that SHIP1 associates with the death receptor CD95/Fas and treatment with a Caspase8 inhibitor prevents SHIP1 inhibitor mediated T cell death. Notably, mucosal inflammation in SHIP1 −/− mice is reduced by treatment with a Caspase8 inhibitor. We also find that the incidence of CD and pneumonia are significantly increased in mice with dual T and myeloid lineage SHIP1 deletion, but not in single lineage deleted mice. Thus, by promoting survival of protective T cells, thereby preventing an inflammatory myeloid response, SHIP1 maintains an appropriate balance of innate immune function at mucosal surfaces necessary for immune homeostasis.
INTRODUCTION
Previously we found that SHIP1-deficient hosts develop a profound ileitis that closely resembles human Crohn's Disease (CD) with many SHIP1 −/− mice developing strictures and fissures in the terminal ileum 1 . The cause of this mucosal inflammatory disease was not defined in our initial study. However, we did observe a pronounced reduction of both CD4 + and CD8 + T cells accompanied by a predominantly neutrophilic infiltration of the small intestine in SHIP1 −/− mice 1 . The terminal ileum is not the only inflamed mucosal site in the SHIP1 −/− host as a myeloid consolidation of the lungs is routinely observed in both germline SHIP1 −/− mice 2 and following ablation of SHIP1 expression in adult mice 3 . Thus, myeloid inflammatory disease at mucosal sites is thought to lead to the early demise of SHIP1 −/− mice 1, 2 . These inflammatory processes are likely triggered by microbiological cues, as housing of SHIP1 −/− mice in specific pathogen free (SPF) conditions, although failing to restore normal lifespan, does extend the survival of SHIP1 −/− mice 4 .
Although SHIP1 −/− mice show a reduced frequency of T cells in the spleen 2 , this is simply a reflection of their decreased representation due to an expansion of the myeloid compartment. In fact, the absolute number of splenic T cells was found to be normal in two different strains of SHIP1 mutant mice homozygous for distinct mutations, while their numbers were significantly increased in the mesenteric LN 5 . In addition, Treg cell numbers are significantly increased in both the spleen and LN of multiple SHIP1 mutant strains [5] [6] [7] . The above findings and the reduction in the number of T cells in the gut of SHIP1 −/− mice indicates that the classical view of SHIP1 as solely an inhibitor of PI3K mediated survival can not be universally applied to all T cell types in all tissue locations. Adding to the complex role of SHIP1 in regulation of T cell survival is recent evidence that Jurkat T cells that have severely diminished SHIP1 expression are sensitive to FasL mediated apoptosis 8 . Thus, SHIP1 may have divergent roles in the control of T cell survival that vary with T cell type, tissue location or the mechanism of cell death (e.g., intrinsic vs extrinsic pathway). A more nuanced understanding of this complexity, and particularly in normal physiology and different disease settings may then provide therapeutic insights for T cell mediated autoimmune diseases, T cell neoplasms and cancer treatment by adoptive transfer of T cells.
In certain forms of inflammatory bowel disease (IBD), including both Crohn's disease (CD) and ulcerative colitis (UC), autoreactive T cells that are resistant to apoptosis are thought to promote inflammation and tissue damage 9, 10 . Compelling evidence supporting this view has been elusive, however, with an alternate hypothesis being put forward that CD could be the result of an immune deficiency involving T cells and perhaps other inflammatory cell types 11 . Our finding of a selective T cell deficit in the small intestine of SHIP1 −/− mice is consistent with this latter view 1 . Moreover, in chronically infected HIV patients where there is a severe depletion of intestinal CD4 + T cells, the incidence of mucosal inflammation in these patients is very high 12 . Importantly T cells from these patients are very sensitive to activation induced cell death (AICD) [13] [14] [15] . In addition, long-lived non-recirculating memory T cells that are Fas + require highly efficient regulation to avoid incidental Caspase 8 activation to prevent depletion of these cells that are necessary for immune surveillance in the gut 16 . Maintaining a proper balance of survival vs. apoptosis in mucosal resident T cells is likely required then for immune surveillance at the mucosal barrier and thus for maintenance of an appropriate balance of adaptive vs. innate immune function in the mucosa. Further elucidation of the mechanisms that determine survival vs. apoptosis in gut resident T cells is then critical for better understanding the basis of IBD in genetic conditions and during immune suppression like that which occurs in AIDS.
Due to the T cell deficit observed in the small intestine of SHIP1 −/− mice, we proposed that SHIP1 signaling might be required for the persistence of effector T cells at mucosal sites. A selective defect in the ability of effector T cells to survive at mucosal sites would obviously also impair their capacity to participate in immune surveillance at these sites. We then hypothesized that decreased T cell effector function at mucosal sites in germline SHIP1-deficient mice would lead to an over-response by SHIP1-deficient neutrophils and other inflammatory myeloid cells to incitements like commensal microflora or crystal formation by bronchial epithelial cells culminating in severe, life-compromising tissue destruction by myeloid cells 1 . This hypothesis exemplifies the duality of SHIP1's role in immune cell signaling, manifesting as either an activator or inhibitor of immune function depending on the involved cell or receptor complex 17 . We show here that the impaired persistence of SHIP1 −/− T cells is due to their enhanced susceptibility to Caspase 8 mediated cell death. Our findings thus represent a novel function of SHIP1 in promoting resistance of T cells to extrinsic cell death selectively at mucosal sites like the small intestine.
RESULTS

Selective reduction of T cells in the small intestine and lungs of SHIP1 −/− mice
We investigated whether reduction in CD4 and CD8 T cells is restricted to the small intestine or whether the other inflamed mucosal site, lung, is also affected by SHIP1 deficiency. CD4 and CD8 T cells are significantly decreased in the small intestine and lungs of SHIP1 −/− mice as compared to WT controls (Figure 1a To test whether reduction of mucosal T cells is due to the inflammatory background of SHIP1 −/− mice or whether it is due to an intrinsic function of SHIP1, a T cell specific deletion model of SHIP1, CD4CreSHIP flox/flox , was examined. This analysis showed that frequency and absolute numbers of both CD4 and CD8 T cells is significantly reduced in CD4CreSHIP flox/flox mice as compared to SHIP flox/flox controls in both the SI and lungs (Figure 2a,b) . Reduction of both T cell lineages in CD4CreSHIP flox/flox mice was selective for mucosal tissues as no differences were observed in CD4 and CD8 T cell frequencies or in the absolute numbers in the spleens (Figure 2c 
Defective survival of SHIP1-deficient T cells
We further examined the requirement for SHIP1 in mucosal T cell persistence by developing a direct competition assay (DCA) for T cells that we and others have used to assess gene function in hematopoietic stem cells (HSC) 19 . In the T cell version of the DCA, CD45.1 + 45.2 + hemizygous C57BL6 mice are sublethally irradiated and reconstituted with equal numbers of WT (CD45.2) and SHIP1 −/− (CD45.1) CD3 + T cells. One month later the mice are sacrificed and their lungs, small intestines and spleen analyzed by FACS to determine the contribution of WT, SHIP1 −/− and host T cells to these compartments ( Figure  3 ). The DCA assay revealed that SHIP1 expression is required for persistence of both CD4 + and CD8 + T cells in the lungs (Figure 3a ) while only CD4 + T cells require SHIP1 for persistence in the lamina propria of the small intestine (SI) (Figure 3b ). Interestingly, we also observed reduced number of SHIP1 −/− CD4 and CD8 T cells in the spleens (Figure 3c ) of these mice suggesting that in a competitive setting like the DCA assay, peripheral SHIP1 −/− T cells are not able to homeostatically expand and survive as well as WT T cell s.
SHIP1 is not required for T cell trafficking to mucosal tissues
As SHIP1 deficiency resulted in reduced engraftment of T cells in mucosal tissues, we further examined whether the impaired numbers of SHIP1 −/− T cells at these sites after competition is due to a defect in trafficking of SHIP1 −/− T cells to mucosal sites rather than just a defect in their survival. To test this possibility equal numbers of WT (CD45. 
SHIP1 sets a threshold for Caspase 8 mediated cell death in T cells
Due to their selective depletion it is not feasible to obtain sufficient numbers of T cells from the small intestine of SHIP1 −/− mice for ex vivo biochemical studies. Thus, we utilized HSB2, a human T cell line that expresses endogenous SHIP1 at normal levels as an alternative model to gain mechanistic insights into how SHIP1 regulates extrinsic T cell death. As anticipated, we find that the SHIP1 selective inhibitor 3AC 3 promotes Caspase 8 mediated cell death in HSB2 T cells. We find that 3AC treatment of HSB2 cells triggers a significant increase in Caspase 8 activation (Figure 6a ) as well as FasL induction ( Figure 6b ). Importantly, we observe that the SHIP1 inhibitor-induced extrinsic cell death in HSB2 T cells is largely prevented by treatment with a Caspase 8 inhibitor prior to SHIP1 inhibition-demonstrating that SHIP1 inhibitor mediated cell death in T cells is preferentially through the Caspase 8 mediated extrinsic cell death pathway (Figure 6c ). Interestingly, we also observed association of SHIP1 with Fas in HSB2 T cells, suggesting that interaction of SHIP1 with CD95/Fas may antagonize signaling by this death receptor and thereby set a threshold for Caspase 8 activation (Figure 6d ). The absence of a SHIP1-mediated negative regulatory mechanism renders T cells more susceptible to Fas-FasL mediated cell death. These findings suggest two possible molecular roles for SHIP1 in preventing inappropriate activation of Caspase 8 in T cells (Figure 6e) , and possibly in other immune cell types.
Caspase 8 inhibitor protects T cells in the mucosa and abrogates inflammation in SHIP1 −/− mice
To assess whether the extrinsic cell death pathway was a major contributor to the demise of 
DISCUSSION
An efficient balance of T cell proliferation and apoptosis is required to achieve a fully functional T cell compartment, which is essential in achieving a proper defense against pathogens and to prevent hyper immune response against self-antigens. In T cells the FasFasL mediated programmed cell death pathway is a fundamental mechanism that eliminates hyper reactive or autoreactive T cells and this regulation is important for immune tolerance 22, 29 . The susceptibility to Fas-FasL mediated cell death varies among different T cell subtypes, as naïve T cells are largely Fas negative and resistant to apoptosis, while effector and memory T cells are Fas positive and more sensitive to apoptosis 30 . The lamina propria of the gut is mostly populated with Fas expressing effector and memory T cells and thus this compartment is acutely sensitive to Fas-mediated cell death 16 . The molecular basis of the survival of these Fas-FasL sensitive lamina propria T cells in spite of constant stimulation by commensal and pathogenic microorganisms present at the mucosal barrier is not fully understood. Our findings demonstrate an important role of the inositol phosphatase SHIP1 in promoting resistance by mucosal T cells to Fas-mediated cell death. Herein we demonstrate that SHIP1 may prevent Caspase 8 mediated cell death in T cells by two mechanisms that are not necessarily mutually exclusive: (1) SHIP1 associates with Fas to antagonize its activation of Caspase 8 and/or (2) SHIP1 inhibits inappropriate FasL induction (Figure 6e ). We propose that one or both of these molecular roles is preferentially operative in SHIP1 −/− lamina propria T cells, where T cells are chronically exposed to pathogens and thus more susceptible to Fas-mediated cell death. Hence, a concerted effect of both SHIP1 activities may prevent inappropriate depletion of T cells in mucosal sites like the SI. However, despite strong evidence for diminished SHIP1 −/− T cell survival in the gut, defective trafficking of these cells to the gut may also contribute, in part, to decreased T effector cell numbers at mucosal sites in SHIP1 −/− mice.
Interestingly we have observed depletion of effector T cells but not Treg cells in the lungs
and SI of SHIP1 −/− mice. In fact, FoxP + 3 CD25 + T cells are increased in the inflamed lamina propria and lungs of SHIP1 −/− mice. Increased Treg cell numbers in mucosal tissues are consistent with the earlier reports of increased Treg cell numbers in the spleen and LN of SHIP1 −/− mice [5] [6] [7] . In addition, SHIP1 −/− Treg cells were found to be equally suppressive as WT in vitro and in vivo, including in a colitis model, 5, 7 indicating that mucosal inflammation does not result from a selective loss of Treg cells and their immunosuppressive properties at mucosal sites.
Our findings also reinforce the duality of SHIP1's role as both a terminator and a mediator of PI3K-mediated cell signaling 17 . In myeloid cells SHIP1 clearly has a pro-apoptotic role as SHIP1 −/− mice exhibit myeloproliferative disorders with increased infiltration of myeloid cells in all the secondary lymphoid organs 2, 31 . In contrast, SHIP1 also functions to prevent Fas-FasL induced cell death in T cells by modulating Fas signaling as well as FasL induction. This observation is supported by the observed association of SHIP1 with Fas (CD95), increased frequency of FasL + T cells in the SI of SHIP1 −/− mice and increased expression of FasL caused by SHIP1 inhibition suggesting that SHIP1's function is both cell type and tissue dependent. Since the susceptibility to Fas-mediated apoptosis differs in naïve, effector, regulatory and memory T cells, it would be interesting to determine if SHIP1 is responsible for the differential sensitivity of these T cell subsets to Fas/FasL mediated programmed cell death.
Our finding that despite their expression of FasL, Treg cell numbers are increased in mucosal tissues of SHIP1 −/− mice is consistent with other studies demonstrating that FasL + Tregs are potent killers of effector T cells [25] [26] [27] [28] . More recently such "killer Treg cells" were implicated in autoimmune diseases due to their enhanced ability to deplete effector T cells as compared to Treg cells that lack FasL [32] [33] [34] . Additionally the susceptibility of Treg cells to undergo FasL-mediated apoptosis has not been unequivocally demonstrated 25, 27, 28 . In the case of SHIP1-deficiency, we observed that SHIP1 −/− Tregs do not undergo apoptosis at an increased frequency and thus these the increased numbers of FasL + Treg cells are likely to contribute to the depletion of effector T cells that we observe in mucosal tissues of SHIP1-deficient mice.
In inflammatory bowel diseases (IBD) like ulcerative colitis and Crohn's disease it has been reported that exaggerated responses by T cells mediates tissue damage and inflammation. Moreover, T cells isolated from these patients have been shown to be resistant to Fasmediated cell death 9, 10 . However in SHIP1 −/− mice T cells do not cause inflammation, but rather the loss of effector T cell function due to their increased apoptosis combined with increased infiltration of myeloid cells results in inflammation. With the recent advances in IBD there is evidence that IBD is a consequence of an impaired acute inflammatory response 11, 35 . SHIP1 −/− mouse model of IBD is consistent with the later view and therefore might used to define IBD states that result from T cell deficiency rather than T cell overreaction.
We found that the human leukemic T cell line HSB2 is sensitive to extrinsic cell death triggered by a selective SHIP1 inhibitor, 3AC, indicating protection of T cells from extrinsic cell death may be a conserved function of human SHIP1/INPP5D. SHIP1 inhibitory compounds may therefore have therapeutic utility in IBD by selectively depleting autoreactive T cells in mucosal tissues such as the small intestine and bowel 3, 36 . Recently T cell depletion strategies have been proposed to control inflammatory bowel diseases (IBD) mediated by autoreactive T cells 37 . Should these findings be extrapolated to the human setting, then treatment with SHIP1 inhibitory compounds might be used alone or in conjunction with such antibody depletion therapies to selectively deplete disease causing T cells at mucosal sites while sparing the bulk of the peripheral T cell pool.
METHODS
Mouse strains
The development and production of SHIP1 −/− (CD45.1) has been described previously 38 . SHIP1 ΔIP/ΔIP mice were a kind gift of Dr. Jeffery Ravetch (Rockefeller University, NY) and for this study were maintained on the F2(129S/v × C57BL6) background described in Karlsson et al 39 . Mice with germline transmission of a SHIP1 flox allele were generated previously in the laboratory 38 
Gut and lung histopathological analysis
Gut and lungs were insufflated with 10% neutral-buffered formalin, the small intestines were rolled in segments to fit as Swiss rolls into cassettes for histological processing and microscopic evaluation. Tissues were fixed in 10% neutral-buffered formalin, dehydrated, embedded in paraffin, sectioned at 3 μm and stained with H&E. Intestinal inflammation was scored as described previously 1 .
Cell preparation and flow cytometry
Lungs were cut into small pieces and lymphocytes were isolated by incubating tissue in digestion buffer containing 5% FBS, 1.5mg/ml Collagenase and 40μg/ml in HBSS for 30 min at 37°C. For isolation of lamina propria T cells, Payer's patches were removed and the small intestines was opened longitudinally and cut into small pieces (1.5 cm). Epithelial cells were removed by incubating tissue (2X) in buffer containing 2mM EDTA and 5% FBS in HBSS for 20 min. Tissue was then digested with 1.5mg/ml Collagenase and 40μg/ml for 30 min at 37°C. Isolated cells were then layered on 40/80% percoll gradient (GE healthcare) and centrifuged for 20 min at 200 rpm. Cells at the interface of the gradient were collected. Single cell suspensions from spleen, lung and small intestine were incubated with anti-CD16/32 to block Fc receptor binding (BD Pharmingen (San Jose, CA) followed by staining with flourochrome-conjugated antibodies. All samples were acquired on an LSRII cytometer (Becton Dickinson) and analyzed using FlowJo software. Dead cells were excluded from the analyses following cytometer acquisition by exclusion of cells that stained positively for DAPI dye.
Mucosal T cell competition assay in CD45.1/2 hemizygous C57BL6 hosts
Spleens of CD45.1 SHIP1 −/− and CD45.2 WT mice were harvested and CD3 + T cells were magnetically purified using a MACS CD3 + Cell selection Kit via tail vein injection. Prior to T cell transplant recipients CD45.1/2 hemizygous C57BL/6 mice received a single dose of 5.5Gy from an X-ray irradiator and then were adoptively transferred with 10×10 6 WT (CD45.2) and 10×10 6 SHIP1 −/− (CD45.1) CD3 + T cells via tail vein injection. One month after ACT, the recipients were sacrificed for lung and small intestine harvest and the lymphocytes of these tissues assessed by flow cytometry.
SHIP1 inhibition (SHIPi) in vitro
HSB2 T cells were plated in 6 well plates in triplicate and treated with 7.5μM 3AC or vehicle (absolute ethanol). After 48h cells were incubated with CaspGLOW fluorescein active for 1h, harvested, washed and stained with Annexin V and propidium iodide (PI). Viable cells were gated on the basis of exclusion of PI and were analyzed for staining of Annexin V and active Caspase 8. For FasL induction, HSB2 cells after 48h treatment with 3AC (7.5μM) were washed and stained with anti-human CD178PE antibody (Ebioscience, San Diego, CA). Analysis of FasL expression on viable cells was performed on the basis of exclusion of DAPI + cells. To assess Caspase 8 inhibitor mediated cell death rescue in 3AC treated cells, HSB2 cells were plated in triplicate and treated with either Caspase 8 inhibitor (Z-IETD-FMK) (50μM) or vehicle for 2h prior to 3AC (7.5μM) treatment. After 24h cells were washed and stained with Annexin V and PI. All samples were acquired on an LSRII cytometer (Becton Dickinson) and analyzed using FlowJo 9.4.1.
Fas-SHIP1 co-immunoprecipitation
HSB2 cells were washed twice with cold PBS and lysed in cell signaling IP lysis buffer (20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM Sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na 3 VO 4 , 1 μg/ml Leupeptin and 1mM PMSF). Equal amount of protein was immunoprecipitated by using anti-Fas or an isotype control antibody (Santa Cruz, CA) along with protein A/G PLUS agarose beads (Santa Cruz, CA) overnight at 4°C. Immunoprecipitates were washed five times with cold lysis buffer and the pellet was resuspended in SDS sample buffer. Samples were heated at 100°C for 5 min and subjected to SDS PAGE. Association of SHIP1 with Fas was determined by probing with anti-SHIP1 (P1C1, Santa Cruz, CA) antibody.
Mucosal T cell competition in CD45.1/2 hemizygous C57BL6 hosts
Spleens of CD45.1 SHIP1 −/− and CD45.2 WT mice were harvested and CD3 + T cells were magnetically purified using a MACS CD3 + Cell selection Kit via tail vein injection. Prior to T cell transplant recipients CD45.1/2 hemizygous C57BL/6 mice received a single dose of 5.5Gy from an X-ray irradiator and then were adoptively transferred with 10×10 6 WT (CD45.2) and 10×10 6 SHIP1 −/− (CD45.1) CD3 + T cells via tail vein injection. One month after ACT, the recipients were sacrificed for lung and small intestine harvest and the lymphocytes of these tissues assessed by flow cytometry as described above.
Caspase-8 inhibitor treatment of mice
SHIP1 −/− mice were treated either with Z-IETD-FMK (5mg/kg) or vehicle (DMSO) three times each week for 3 weeks. Three weeks after initiation of the treatment, the SI and lungs were harvested, and lymphocytes isolated and then stained with anti-CD3 and DAPI dye. All samples were acquired on an LSR II cytometer and then analyzed using FlowJo 9.4.1.
Statistical analysis
The results are presented as the mean ± standard error of the mean. Statistical analysis was performed using two-tailed Students T-test. A p value < 0.05 was considered statistically significant. 
